Dianthus Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DNTH Nasdaq 2836 dianthustx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dianthus Therapeutics, Inc.

LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis - May 5th, 2026 8:57 pm
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates - May 5th, 2026 3:15 pm
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results - May 5th, 2026 2:01 pm
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1st, 2026 2:30 pm
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism - Apr 27th, 2026 3:04 pm
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Apr 23rd, 2026 3:47 am
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 - Apr 19th, 2026 7:28 am
Dianthus Therapeutics CFO Sells $9.5 Million in Stock - Apr 6th, 2026 1:47 pm
How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart - Apr 2nd, 2026 11:09 pm
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Apr 1st, 2026 1:52 am
Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP - Mar 18th, 2026 3:14 pm
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit - Mar 18th, 2026 12:08 pm
Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm - Mar 15th, 2026 6:49 am
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision - Mar 12th, 2026 6:26 pm
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Mar 12th, 2026 2:01 pm
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - Mar 10th, 2026 8:54 pm
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) - Mar 10th, 2026 6:02 am
Dianthus Therapeutics Has Appreciated 12-Fold Over Two Years. What's Going On? - Mar 9th, 2026 2:23 pm
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering - Mar 9th, 2026 2:01 pm
Top Midday Gainers - Mar 9th, 2026 12:42 pm